The incidence of factor VIII inhibitors in patients with severe hemophilia A
Inhibitor development is a serious complication of hemophilia A treatment. Although studies of inhibitor prevalence had been published earlier,1–3 the possibility that there is increased risk of inhibitor formation with different Factor VIII (F.VIII)-containing products was first raised when heat-treated concentrates were introduced. However, this concern was quickly dropped when it was apparent that heat treatment was necessary to inactivate HIV. As a result, no systematic study during the 1980s directly compared heat treated and non-heat treated F.VIII concentrates.
KeywordsFactor VIII Recombinant Factor VIII Severe Hemophilia Inhibitor Formation Inhibitor Development
Unable to display preview. Download preview PDF.
- 1.C.K. Kasper. Incidence and course of inhibitors among patients with classic hemophilia, Thromb.etDiath.Haem.30:263 (1973).Google Scholar
- 6.J.E. Addiego, Jr., E.D. Gomperts, S.-L. Liu, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography, Thromb.Haem.67:19 (1992).Google Scholar
- 7.J.M. Lusher, P.M. Salzman and Monoclate Study Group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to Factor VIIIC concentrates, SeminHematol 27:1 (1990).Google Scholar
- 8.K. Peerlinck, J. Arnout, J.G. Gilles, J.M. Saint-Remy and J. Vermylen. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate, ThrombHaem. 69:115 (1993).Google Scholar
- 9.F.R. Rosendaal, H.K. Nieuwenhuis, H.M. van den Berg, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands, Blood8:2180 (1993).Google Scholar
- 15.L.E. Lippert, L.M. Fisher and L.B. Schook. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A, Thromb.Haem. 64:564 (1990).Google Scholar
- 17.D. Frommel, J.P. Allain, E. Saint-Paul, et al. HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody, Thromb.Haem.46:687 (1981).Google Scholar
- 18.European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins, ScandJ. Haemat.23:64 (1979).Google Scholar
- 22.M.L. Lee, S. Liu-Maruya, S. Courter and E. Gomperts. Determining inhibitor-development risk in previously untreated hemophilia A patients treated (PUPs) with recombinant factor VIII (recombinate™), Blood80:49la (1992).Google Scholar
- 26.R. De Biasi, A. Rocino, M.L. Papa and E. Salerno. Incidence of inhibitor development in hemophilia A patients, Thromb.Haem.69:1103 (1993).Google Scholar
- 27.G.L. Bray, E.D. Gomperts, S. Courter, et al. A multi-center study of recombinant factor VIII (Recombinate):Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A, Blood(1993).Google Scholar